Topoisomerase I inhibitors: review and update (Q41634169)

5 October 2017

1 reference

title

Topoisomerase I inhibitors: review and update (English)

1 reference

5 October 2017

M L Rothenberg

1

1 reference

5 October 2017

1 September 1997

1 reference

5 October 2017

1 reference

5 October 2017

8

1 reference

5 October 2017

9

1 reference

5 October 2017

837-855

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

5 October 2017

1 reference

7 January 2021

Mechanisms of resistance to topoisomerase inhibitors.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase-I: evidence for cell cycle-independent toxicity

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

DNA fragmentation induced by protease activation in p53-null human leukemia HL60 cells undergoing apoptosis following treatment with the topoisomerase I inhibitor camptothecin: cell-free system studies

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

New natural products in cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Synthesis of water-soluble (aminoalkyl)camptothecin analogs: inhibition of topoisomerase I and antitumor activity

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Phase I and pharmacokinetic trial of weekly CPT-11

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Phase I Study and Pharmacokinetics of CPT-11 With 5-Day Continuous Infusion

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Phase I study of CPT-11 and etoposide in patients with refractory solid tumors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Simultaneous administration of CPT-11 and fluorouracil: alteration of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Irinotecan is an active agent in untreated patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Phase I Study of Weekly Intravenous Infusions of CPT-11, a New Derivative of Camptothecin, in the Treatment of Advanced Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Phase I study of topotecan for pediatric patients with malignant solid tumors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Phase II study of topotecan in metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Phase II study of topotecan in metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Phase II study of topotecan in patients with recurrent malignant glioma. National Clinical Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Topotecan in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Phase II trial of topotecan in patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumors.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Phase II evaluation of topotecan for pediatric central nervous system tumors.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Topotecan in colorectal cancer: a phase II study of the EORTC early clinical trials group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Pharmacodynamics and pharmacokinetics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Hypersensitivity of NIH3T3 cells transformed by H-ras gene to DNA-topoisomerase-I inhibitors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

HT1080/DR4: a P-glycoprotein-negative human fibrosarcoma cell line exhibiting resistance to topoisomerase II-reactive drugs despite the presence of a drug-sensitive topoisomerase II.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Apoptosis induced by DNA topoisomerase I and II inhibitors in human leukemic HL-60 cells.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Induction of mammalian DNA topoisomerase I and II mediated DNA cleavage by saintopin, a new antitumor agent from fungus

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

New naphthacenecarboxamide antibiotics, TAN-1518 A and B, have inhibitory activity against mammalian DNA topoisomerase I

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Induction of mammalian DNA topoisomerase I mediated DNA cleavage by antitumor indolocarbazole derivatives

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

DNA minor groove-binding ligands: a different class of mammalian DNA topoisomerase I inhibitors.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

The antileukemic alkaloid fagaronine is an inhibitor of DNA topoisomerases I and II.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Topoisomerase I activity and cellular response to radiation in Chinese hamster cells

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Interaction of ionizing radiation with topotecan in two human tumor cell lines

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008270717294

7 January 2021

Identifiers

DOI

10.1023/A:1008270717294

1 reference

5 October 2017

1 reference

PubMed ID

9358934